Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Imlifidase by Hansa Biopharma for Guillain-Barre Syndrome: Likelihood of Approval
Imlifidase is under clinical development by Hansa Biopharma and currently in Phase II for Guillain-Barre Syndrome. According to GlobalData, Phase...